A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Código QR

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Chung-Shien Lee,1,2 Sandhya Sharma,3 Emily Miao,4 Cheryl Mensah,5 Kevin Sullivan,2 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, College of Pharmacy and Health Sciences, Queens, NY 11439, USA; 2Division of Medical Oncology and Hematology, Northwel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8b542e20ae0a4c32b9f76e780154d06b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
por: Ling-Ling Kong, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Liesbeth M. Hondelink, MD, et al.
Publicado: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
por: YingYing He, et al.
Publicado: (2021)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
por: Ana Podolski-Renić, et al.
Publicado: (2021)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
por: Skye Montoya, et al.
Publicado: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
por: Hyeok-Jae Jang, et al.
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
por: Masatomo Ueda, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti F, et al.
Publicado: (2019)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev B, et al.
Publicado: (2016)

Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma
por: Andrea Pontara, et al.
Publicado: (2020)

The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
por: Kamil D. Kaplanov
Publicado: (2021)

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
por: Raj Kumar Mongre, et al.
Publicado: (2021)

The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice
por: Zhongju Lu, et al.
Publicado: (2021)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Agnieszka Kaczmarska, et al.
Publicado: (2021)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Ling Peng, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
por: Adina Gerson-Gurwitz, et al.
Publicado: (2021)

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
por: Tran PN, et al.
Publicado: (2016)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan BK, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
por: Anna K. Kamitakahara, et al.
Publicado: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021)

Oligoprogression in Non-Small Cell Lung Cancer
por: Daijiro Harada, et al.
Publicado: (2021)